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Abstract
Background—Management of osteoarthritis (OA) requires both medical and behavioral 
strategies, but there is low use of some recommended therapies.
Objectives—This study examined the effectiveness of a combined patient and provider 
intervention for improving OA outcomes.
Design—Cluster randomized clinical trial with assignment to OA Intervention and Usual Care 
arms.
Setting—Department of Veterans Affairs Medical Center (VA) in Durham, NC, USA.
Participants—30 providers (clusters) and 300 outpatients with symptomatic hip and / or knee 
OA
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Interventions—The telephone-based patient intervention focused on weight management, 
physical activity, and cognitive behavioral pain management. The provider intervention involved 
delivery of patient-specific OA treatment recommendations to primary care providers through the 
electronic medical record.
Measurements—Primary outcome: Western Ontario and McMasters Universities Osteoarthritis 
Index (WOMAC) total score (range: 0-96) at 12 months. Secondary outcomes: WOMAC function 
subscale (range: 0-68), WOMAC pain subscale (0-20), physical performance (Short Physical 
Performance Battery) and depressive symptoms (Patient Health Questionnaire-8). Linear mixed 
models adjusted for clustering of providers assessed the difference in improvement in outcomes 
between arms.
Results—At 12-month follow-up, WOMAC scores were 4.1 points lower (indicating 
improvement) in the OA Intervention arm vs. Usual Care [95% confidence interval (CI) = −7.2, 
−1.1; p=0.009]. The WOMAC function subscale was 3.3 points lower in the intervention arm 
[95% CI = −5.7, −1.0; p=0.005]. There was no difference in WOMAC pain subscale scores 
between arms (p=0.126). Physical performance and depressive symptoms did not differ between 
the two arms.
Limitations—The study was conducted in one VA medical center.
Conclusions—The combined patient and provider intervention resulted in modest improvement 
in self-reported physical function in patients with hip and knee OA.
Primary Funding Source—National Institute of Arthritis and Musculoskeletal and Skin 
Disorders
Clinical Trial Registration Numbers—NCT01130740
Background
Osteoarthritis (OA) is one of the most common chronic health conditions and a leading 
cause of pain and disability (1-5). The prevalence of OA is on the rise, and this trend is 
expected to continue (6, 7). In addition to the substantial toll at the individual level (8), OA 
is placing an increasing burden on healthcare systems (9, 10).
Evidence-based guidelines indicate that adequate management of hip and knee OA requires 
both behavioral and clinical strategies (11-14). Physical activity and weight management are 
key behavioral strategies for managing hip and knee OA, but the majority of adults with OA 
are physically inactive and / or overweight (15, 16). Similarly, despite strong evidence 
supporting several clinical strategies (e.g., joint injections, physical therapy, pain 
medications), some of these treatments are under-utilized, and studies have shown lrates of 
adherence to OA quality indicators (17-20). There is a need to improve the OA management 
at both patient and provider levels. The purpose of our study was to examine a combined 
patient and provider intervention for managing OA in primary care.
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The institutional review board of the Department of Veterans Affairs Medical Center in 
Durham, NC (DVAMC) approved this study. Detailed methods have been published 
previously (21).
Study Design
This was a cluster randomized controlled trial, with primary care providers (PCPs) assigned 
to OA Intervention or Usual Care control. Randomization was computer-generated, 
maintained by the study statistician, and stratified based on providers’ volume of female 
patients (<15% vs. ≥15%). We aimed to enroll ten patient participants, five white and five 
non-white, from each of 30 PCPs. PCPs assigned to the OA Intervention received the 
Provider Intervention, and their enrolled patient participants received the Patient 
Intervention. Patient participants in both arms continued with any usual medical care 
recommended by their providers. Since all study participants were patients enrolled at the 
DVAMC, usual care could include any of standard treatments for OA given by a PCP and 
referral to other providers or specialists. Provider and patient participants in the Usual Care 
arm received no additional intervention during the study period.
Participants and Recruitment
PCPs in the DVAMC Ambulatory Care Service with patient panels large enough to likely 
enroll n=10 participants were invited to participate. Patients were eligible if they had hip OA 
(based on radiographic evidence in the electronic medical record (EMR)) and / or knee OA 
(based on radiographic evidence in the EMR or meeting American College of 
Rheumatology clinical criteria (22)), along with patient-reported joint symptoms ( “pain, 
aching, stiffness or swelling in or around a hip or knee joint with arthritis” that was present 
or for which patient used pain medications on most days during the last month (23). 
Participants also had to be overweight (body mass index (BMI) ≥ 25) and not currently 
meeting Department of Health and Human Services physical activity recommendations (24). 
Exclusion criteria are summarized in Appendix A. Potential participants were identified 
from the DVAMC EMR, mailed an introductory letter and called for a screening interview. 
Eligible patients came to the DVAMC to complete consent and baseline assessments and 
were subsequently informed of their randomization assignment via telephone. Study team 
members involved in screening and consent were blinded to randomization. Potential patient 
participants were blinded to their PCP’s randomization until after baseline assessments.
Interventions
Patient Intervention—This was a twelve-month intervention focusing on physical 
activity, weight management and cognitive behavioral pain management strategies (21). 
Telephone calls were scheduled twice per month for the first six months, then monthly for 
the last six months, and were delivered by one counselor with training in OA and behavior 
change. Goal-setting and action-planning were major components of the intervention. 
Motivational interviewing strategies were employed by the counselor throughout the 
intervention (21, 25, 26). Participants were given written patient educational materials 
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corresponding to intervention topics, an exercise video for patients with OA, and an audio 
CD of relaxation exercises.
Provider Intervention—This intervention involved delivery of the following patient-
specific OA treatment recommendations to PCPs, based on published treatment guidelines 
(13, 14, 27): Refer to physical therapist, Refer for evaluation for knee brace, Refer to 
MOVE! (VA’s weight management program that includes physical activity counseling 
(28)), Perform or refer for intra-articular injection, Recommend topical NSAID or capsaicin, 
Add gastroprotective agent or remove NSAID, Discuss possibility new / alternate pain 
medication, Refer to orthopedic evaluation for joint replacement surgery. We developed 
algorithms (Appendix B) to determine when each treatment option may be reasonable for a 
PCP to consider for a patient (21). Study team members collected all information needed to 
complete the algorithm for each patient participant during baseline assessments. Patient-
specific recommendations were delivered to PCPs via the EMR as a progress note requiring 
e-signature. The study team monitored upcoming visits for OA Intervention participants, and 
recommendations were delivered to PCPs about one week prior to participants’ first routine 
visit after enrollment. The recommendations remained available to PCPs within the EMR, 
but no further communications were transmitted to OA intervention providers.
Outcome Measures
Baseline and 12-month follow-up measures were completed in person, except for n=36 
participants who could not return to the Durham VAMC at 12-months but completed some 
measures via telephone. The primary outcome was also assessed via telephone at 6-months. 
Outcomes assessors were blind to randomization. Participants were reimbursed $25 and $10 
for completing in-person and phone assessments, respectively.
Primary Outcome—The primary outcome measure was the Western Ontario and 
McMaster Universities Osteoarthritis Index (WOMAC), a self-report measure of lower 
extremity pain (5 items), stiffness (2 items), and function (17 items) in the past two weeks 
(29-31). All items are rated on a 5-point Likert scale ranging from “none” to “extreme,” 
(total score range, 0=96, higher scores indicate worse symptoms and function).
Secondary Outcomes—We separately examined the WOMAC pain and function 
subscales. We also administered the Short Physical Performance Battery (SPPB) (32), a 
commonly used performance measure in older adults that includes three tests of balance, a 
timed 8-foot walk, and five chair stands. The total score ranges from 0 (worst performance) 
to 12 (best performance). . Depressive symptoms were assessed with the Patient Health 
Questionnaire-8 (PHQ-8) (33), with scores ranging from 0-24.
Process Measures—We collected additional “process measures” related to behaviors or 
outcomes intermediate to changes in symptoms or function. Self-reported physical activity 
was measured with the Community Health Activities Model Program for Seniors 
(CHAMPS) (34, 35), which assesses the frequency and duration of light to vigorous 
activities during the past four weeks; we report the weekly frequency and duration of all 
exercise, as well as moderate or higher intensity exercise. The CHAMPS has established 
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test-retest reliability and association with accelerometer-based physical activity among older 
adults (36). BMI was calculated using measured height and weight; when 12-month follow-
up measures were administered via telephone, weight was self-reported.
For all patient participants, we used the DVAMC EMR to examine PCPs’ OA-related 
referrals, as well as participants’ actual visits for physical therapy, knee braces, joint 
injections, MOVE!, and orthopedic consultation during their study period. We assessed 
changes in oral and topical pain medication by participant self-report. For oral pain 
medications, we defined new use during the study period as: a.) no pain medication use at 
baseline but some pain medication use at follow-up, OR b.) taking a different pain 
medication at follow-up than at baseline. For topical creams, we defined new users as those 
who reported using any type at follow-up but not at baseline. We acknowledge that use of 
new oral or topical pain medications may not necessarily lead to better pain control. For OA 
Intervention participants, we also report proportions whose PCP received each treatment 
recommendation from the study team, and among those, proportions who had referrals and 
visits for those treatments.
Participant Characteristics—We collected patient participant-reported age, gender, 
race/ethnicity (white vs. non-white), household financial situation ( “inadequate income” 
defined as participants who reported that they “just meet basic expenses” or “don’t even 
have enough to meet basic expenses”), education level, marital status, work status 
(employed or student vs. other), disabled (positive response to “disabled” in the work status 
question, regardless of other response(s) selected), self-rated health (excellent, very good or 
good vs. fair or poor), and duration of OA symptoms. We also report presence of OA in the 
knee only, hip only or both, based on enrollment data described above. For provider 
participants, we collected information on clinician category (physician, nurse, nurse 
practitioner or physician assistant), gender and whether the patient panel was <15% or ≥15% 
female.
Adverse Events—We inquired at each study encounter about hip and knee injuries or 
surgeries, per protocol. Information about other adverse events was noted when participants 
informed the study team during a regular contact, or when an event was discovered during 
study-related review of medical records.
Sample Size
Our sample size of 300 patient participants was based on detecting a moderate effect size of 
approximately 0.30 for the difference in mean WOMAC scores between arms, with 80% 
power and a type-I error rate of 0.05. This translates to a 4.2 point difference at 12-months, 
which is equivalent to approximately 11% improvement from anticipated mean baseline 
score; this allowed sufficient power to detect a clinically relevant difference (12-18% based 
on prior relevant literature) (37-39). We used a two-sample t-test sample size calculation for 
the between arm difference at 12-months, multiplied by a factor 1-(rho)^2, where rho 
represents the Pearson correlation between baseline and follow-up outcome measures (0.60) 
(40). This sample size was then adjusted to reflect provider clustering using an intraclass 
correlation coefficient (ICC) of 0.02(41) and inflated to compensate for potential attrition 
Allen et al. Page 5
















(12%). Based on our pilot work we assumed a mean baseline WOMAC score of 38 with a 
standard deviation of 14.
Data Analyses
Our primary hypothesis was that OA Intervention participants would have significantly 
greater improvement in WOMAC scores than Usual Care. Analyses involved all randomly 
assigned participants using all data collected (42). Observations were not deleted due to 
missing follow-up data (43). The estimation procedure for our analytic technique (linear 
mixed models) implicitly accommodates missingness when related to prior outcome, or to 
other baseline covariates in the model (defined as missing at random (MAR)). To assess the 
primary model’s robustness to missing observations, we multiply imputed missing WOMAC 
follow-up scores using a Markov chain Monte Carlo (MCMC) algorithm incorporating 
additional variables beyond those in the linear mixed effects models to strengthen the MAR 
assumption (Appendix C).
For primary and secondary outcomes, as well as continuous process measures, linear mixed 
models were fit using the SAS procedure PROC MIXED (44). A random effect to account 
for clustering of primary care providers and an unstructured covariance structure for the 
repeated measures over time were used. For CHAMPS outcomes , change from baseline to 
12-months was used due to normality assumptions. Predictors in all models included dummy 
coded follow-up time effect(s) and an indicator variable for the intervention interacting with 
follow-up time effect(s)(45). This model assumes study arms have equal baseline means, 
which is appropriate for a randomized control trial and is equivalent in efficiency to an 
ANCOVA model (46). The final models also included patient participant race and the 
provider stratification for percentage of female patients . Our primary inference was on the 
treatment by 12-month follow-up time point parameter, as this was the estimated difference 
between arms at the end of the study. For CHAMPS 12-month change from baseline scores, 
model fixed effect terms included baseline CHAMPS score and an indicator variable for 
study arm. For BMI analysis, in-person weight at 12-month follow-up was the outcome; 
sensitivity analyses included self-reported weight from participants without an in-person 12-
month visit.
In a post-hoc analysis to examine clinically meaningful change in WOMAC scores (based 
on prior studies of behavioral and rehabilitative interventions) (37, 39, 47), we categorized 
patients as either improved or not at 12-months, using a 12% improvement in total WOMAC 
score from baseline (5.8 point reduction) and an 18% improvement from baseline (8.7 point 
reduction). We used generalized estimating equation (GEE) models (48) with a logit link 
function and an unstructured correlation structure and used empirical standard errors for 
inference.
Role of the Funding Source
The funding agency approved the project and monitored progress but had no direct role in 
the design or conduct of the study, analyses, or decision to submit the manuscript for 
publication.
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Participant Enrollment and Retention
Forty-three PCPs were approached and 30 were enrolled (Figure 1, Table 1). We identified 
n=5,094 potential patient participants from the EMR. Of 1,503 patients screened by 
telephone, 356 were eligible and 300 were enrolled and randomized (Table 1). There were 
151 patient participants in the OA Intervention and Usual Care arms, respectively. One 
patient was assigned to a Usual Care provider at the beginning of the recruitment process but 
switched to an OA Intervention provider prior to being notified of study group assignment. 
It was determined that the participant should be included in the assigned arm of his provider 
at the time of notification of randomization assignment (OA Intervention).
Among enrolled participants, 88% completed 6-month measures, and 91% completed 12-
month measures (Figure 1). Seventeen participants were excluded before study completion 
for the following reasons : hip / knee replacement or other significant hip / knee surgery 
(n=10), developed serious health condition that would make generalized exercise or diet 
advice risky (n=3), exclusion criteria present that were not identified prior to consent (n=2), 
moved out of area and treatment recommendations could not be issued (n=1), and switched 
from an OA Intervention provider to a Usual Care provider before treatment 
recommendations were issued (n=1).
Intervention Delivery
The average number of participants enrolled per provider was 10.0 (SD=2.1; range 3-12). 
OA Intervention participants completed an average of 11.5 phone calls (SD=4.9) out of 18 
planned calls, and the average length of calls was 16.6 minutes (SD =12.4). For all but eight 
patient participants, the study team was able to deliver treatment recommendation(s) to the 
PCP within the intervention period. Of the eight participants, two were excluded from the 
study, one withdrew, one was reassigned to a non-study PCP who had not yet seen the 
patient, two transferred to another VA Medical Center, and two were inadvertently missed 
by the study team. For some participants (n=26), non-acute visits were scheduled with PCPs 
not enrolled in the study; in all but one case the covering PCP agreed to receive the 
recommendations. The mean number of recommendations issued per patient participant was 
4.6 (SD = 1.8).
Adverse Events
Four study-related adverse events occurred, but none were associated with the OA 
intervention.
Primary Outcome
At 12 months, the estimated mean improvement in WOMAC score was −4.0 points (95% 
Confidence Interval (CI) −6.2, −1.8) in the OA Intervention arm and 0.1 point (95% CI 
−2.1, 2,3) in the Usual Care arm, with an estimated mean difference of −4.1 points (95% CI 
−7.2, −1.1; p=0.008) between arms (Table 2). There was improvement in both arms at 6 
months compared to baseline, with the mean score for the Usual Care arm rebounding to 
baseline levels by 12 months. WOMAC scores also increased between 6 and 12 months for 
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the OA Intervention arm but remained below baseline scores. There was a clustering effect 
for WOMAC scores within provider, with an estimated ICC of 0.02. Similar results were 
found using the multiply imputed datasets (mean difference = −4.2 (95% CI, −7.3 −1.2; 
p=0.007). For the post-hoc analysis examining improvement of 12% or 18% of WOMAC 
score from baseline to 12-months, an estimated 47.2% of participants improved 12% at 12-
months in the OA Intervention arm compared to 37.5% in Usual Care (OR 1.3 95% CI 
(1.0,1.6); p=0.089); 36.1% improved 18% in the OA Intervention arm compared to 28.2% in 
Usual Care (OR 1.3 95% CI (0.9,1.8); p=0.166).
Secondary Outcomes
We found no difference between arms in the WOMAC pain subscale (p=0.52 at 6 months; 
p=0.126 at 12 months, Table 2). However, at 12-months, the estimated mean WOMAC 
physical function score in the OA Intervention arm was 3.3 points (95%CI 1.0, 5.7; 
p=0.005) lower than Usual Care. For objective physical function and depressive symptoms 
we found no differences between arms (Table 2). Because some patient participants 
completed 12-month follow-up assessments by telephone, SPPB scores were missing more 
often at this time point than the self-report measures (see Table 2 for details).
Process Measures
The OA Intervention arm had greater improvement in both the frequency and duration of all 
physical activity at 12-months compared to Usual Care: 3.3 more times per week (p=0.009) 
and 3.6 more hours per week (p=0.003; Table 2). Similar results were found for change in 
physical activity of moderate or greater intensity, with an increase of 1.6 more times per 
week and 1.6 more hours per week in the OA Intervention arm compared to Usual Care 
(p=0.04 and p=0.02, respectively). We found no difference between arms for BMI. Results 
were similar in sensitivity analyses including patient participants for whom weight was self-
reported at 12-months..
OA Treatment Recommendations and Use
Table 3 shows proportions of all patient participants who received specific OA-related 
referrals and treatments or visits during their study period, by study arm. PCP referrals to 
several rehabilitative and behavioral therapies were somewhat higher for OA Intervention 
than Usual Care; these included physical therapy (12% vs. 7%), knee braces (19% vs. 11%), 
and MOVE! (20% vs. 3%). However, the numbers of patients who actually received these 
therapies at the Durham VAMC during the study period were low for both study arms. 
Referrals and receipt of joint injections were similar by arm, as were orthopedic visits. 
Referrals are not needed for topicals, NSAIDs or alternative pain medication. Similar 
proportions of patient participants in the OA Intervention and Usual Care arms reported new 
use of topical creams (NSAIDs or capsaicin) at 12-month follow-up (9% and 7%, 
respectively). Proportions of patient participants who reported using a new or different pain 
medication at follow-up were also similar (36% and 35%, respectively).
Table 4 shows proportions of OA Intervention participants whose PCP received specified 
treatment recommendations from the study team, and of those, proportions who had PCP 
referrals and visits for those treatments. The most commonly issued treatment 
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recommendations were for MOVE! (87%) and discussion of new pain medication (83%). 
PCPs of 16 participants received a recommendation for adding a gastroprotective agent or 
removing from NSAID; data not shown in table since referral and treatment data were not 
obtainable from the EMR. Proportions of participants who received referrals from PCPs 
ranged from 11%-43% of those with a study-issued recommendation. However, numbers of 
participants who received each treatment were low.
Discussion
In this study, a patient and provider OA intervention improved the primary outcome (total 
WOMAC score) at 12-months. WOMAC function subscale scores also improved at 
12months. This is important since OA is one of the main contributors to functional 
limitations in adults (4), leading to loss of abilities to perform daily activities if not 
mitigated. The WOMAC function score makes up a large portion of the total score (68 out 
of 96 total possible points), and this likely drove changes in the primary outcome. The 
intervention also improved physical activity levels. Research indicates only about 10% of 
patients with OA meet physical activity recommendations (49), and increasing activity 
levels in these patients is a high public health priority (50). We found no statistically 
significant or clinically relevant differences between arms for other secondary and process 
outcomes, including the WOMAC pain subscale, depressive symptoms and BMI (51, 52).
Effects of this OA Intervention on WOMAC total and function subscale scores were modest. 
In the context of behavioral and rehabilitative interventions for OA, thresholds for clinically 
meaningful improvement in WOMAC have typically ranged from 12%-18% (37-39). In this 
study we observed an 8.5% improvement in WOMAC total scores and a 9.8% improvement 
in WOMAC function scores in the OA Intervention arm, which are below these thresholds. 
We found that 47% and 36% of OA Intervention patient participants achieved 12% and 18% 
improvement in WOMAC total scores, respectively. Future analyses will examine whether 
specific participant characteristics were associated with differential improvement.
For both study arms, WOMAC scores improved at the interim 6-month follow-up 
assessment, with somewhat greater improvement in the OA Intervention arm. WOMAC 
scores then increased by 12-months (indicating relapse); scores remained improved 
compared to baseline for the OA Intervention arm only. In the OA Intervention arm, the 
decline in response between 6 and 12 months may have been related to the decrease in 
frequency of intervention calls. There are several possible reasons that effects of this 
intervention were smaller than those observed in some other studies of behavioral 
interventions OA (53-57). First, the intervention was less intensive than those examined in 
most prior studies, involving no in-person visits and relatively brief telephone calls. 
Although a low-intensity intervention is appealing from a resource and dissemination 
perspective, more intensive interventions may be necessary to enable patients with OA to 
achieve and sustain clinically relevant improvements. Second, study participants had greater 
pain and functional limitations than in samples from most prior studies of this type (53-55). 
Advanced OA can be more difficult to alleviate with non-surgical options, which may have 
limited treatment benefits for some of our participants. Third, participants also had a high 
level of comorbid physical and psychological health conditions (58), which can contribute to 
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outcomes such as pain, function and depressive symptoms (59). Fourth, most similar studies 
have recruited patients predominantly by self-referral, which may attract primarily highly 
motivated individuals. By approaching patients proactively and inviting them to participate, 
our recruitment strategy was designed to identify a sample that was comparable to a typical 
clinic population in terms of motivation to engage in a lifestyle change intervention. Fifth, 
specifically related to the SPPB, tests included in this battery may not be highly sensitive to 
change in this type of patient sample, and recent recommendations indicate that other 
physical performance tests may be more appropriate in the context of knee and hip OA (60).
This study was novel in its approach to a provider-based intervention for OA, which resulted 
in greater referrals for some treatments, particularly physical therapy, knee braces and 
referral to MOVE!. However, participants’ actual use of these therapies did not differ 
between study arms and was quite low overall. Some participants may have been unwilling 
or unable to return to the DVAMC for additional treatments, since many of these 
participants live relatively far from the facility. Some participants may have received these 
treatments after their observed study period or outside the VA and therefore not captured in 
our data pull. There is a need for additional work to understand reasons patients may choose 
not to initiate key behavioral and rehabilitative therapies for OA, particularly when referred 
by their PCPs. For other clinical treatments addressed in the provider intervention (joint 
injections, medication use, orthopedic referrals), there were no substantial differences 
between study arms. PCPs may already recommend these treatments regularly, as suggested 
by relatively common use of joint injections in both study arms. .
There are several limitations to this study. First, this study design did not allow separate 
examination of patient and provider interventions. Second, participants received care at a 
VA medical center, with a high proportion of men. This may limit generalizability of 
findings. Third, there are limitations to the accuracy of self-reported physical activity data; 
however, we do not suspect this differed between study arms. Fourth, algorithms for 
generating treatment recommendations required more extensive data collection than would 
be feasible in clinical settings. However, simpler sets of criteria could be used to trigger 
these recommendations in clinical situations.
In conclusion, this patient provider intervention resulted in modest improvements in self-
reported physical function and physical activity for Veterans with hip and knee OA. The 
provider-based intervention seemed particularly useful for increasing referrals for behavioral 
and rehabilitative programs. However, changes in study outcomes were modest, which may 
indicate that higher intensity interventions are needed to yield clinically meaningful changes 
in OA-related outcomes.
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Appendix A: Exclusion Criteria
Other rheumatologic conditions
Recent hip or knee surgery or injury
On waiting list for arthroplasty
Recent hospitalization for cardiovascular or cerebrovascular events




Severe hearing or speech impairment
Blindness
Current participation in another OA intervention or other lifestyle change study
Current pregnancy or plans to become pregnant
No primary care visits at the Durham VAMC in the past 12 months
Appendix B: Provider Intervention Recommendations and Algorithms
Refer to physical therapy for evaluation and/or therapeutic exercises
Criteria:
• Patient may be interested in being referred for physical therapy for OA if their 
provider recommends, AND
• Patient is not doing lower extremity strengthening exercises ≥2 times per week, 
AND
• Patient indicates being dissatisfied with their ability to perform one more activities 
on the Satisfaction with Physical Function Scale (walking, lifting / carrying, stair 
climbing, housework), AND
• Patient has not seen a physical therapist for their OA in the past year.
Refer for evaluation for knee brace
Criteria: (for each knee with OA):
• Patient is not currently using a knee brace, AND
• Patient may be interested in trying a knee brace (or different kind of knee brace) if 
their provider recommends.
Criteria for Specific Brace Consults (VA-Based Study Only)
• Knee Sleeve: Knee pain rating 1-3 (on a 10cm visual analog scale) AND varus/
valgus alignment <10°, AND does not indicate knee “buckling”.
• Hinged Brace: Knee pain rating >3 (on a 10cm visual analog scale) OR indicates 
knee “buckling”, AND varus/valgus alignment ≤15°.
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• Unloader Brace: Knee pain >3 (on a 10 cm visual analog scale) OR indicates knee 
“buckling,” AND varus/valgus alignment >15°.
Refer to weight management program (MOVE!)
Criteria:
• Patient has BMI ≥ 25, AND
• Patient may be interested in being referred to a weight management program if 
their provider recommends.
Refer to physical activity program (MOVE!)
Criteria:
• Patient is not doing at least 2 hours and 30 minutes of aerobic activity per week and 
strengthening exercises ≥2 times per week, AND
• Patient may be interested in being referred to a physical activity program if their 
provider recommends.
Perform or refer for Intra-articular injection
Criteria:
• Patient has moderate to severe knee pain (≥6 on a 10cm visual analog scale), AND
• Patient has radiographic evidence of OA in that knee, AND
• Patient is already taking oral pain medications, AND
• Patient has not received a joint injection in the past 6 months, AND
• Patient may be interested in having a knee joint injection if their provider 
recommends.
Recommend or prescribe Topical NSAID or capsaicin
Criteria:
• Patient is not currently using topical creams for OA, AND
• Patient may be interested in trying a topical cream (or different type of topical 
cream) if their provider recommends.
Patient reports taking an NSAID (prescription or OTC) but has risk factors 
for GI bleeding. Consider addition of gastroprotective agent or switch to 
other pain medication
Criteria:
• Patient is currently using an NSAID without gastroprotective agent, AND
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• Patient has one or more risk factors for GI bleeding: age≥ 75 years, history of 
peptic ulcer disease or GI bleeding, current glucocorticoid use.
Discuss the possibility of trying a new/alternate pain medication with 
patient
Criteria:
• Patient indicated they may like to talk with their health care provider about the 
possibility of trying a different pain medication for their arthritis.
Referral to orthopedics for evaluation for joint replacement surgery (if no 
contraindications to surgery)
Criteria:
• Radiographic evidence of OA in that joint, AND
• Patient has tried each of the following: pain medications, joint injection, physical 
therapy, AND
• Pain ≥6 (on a 10cm visual analog scale) in that joint, AND
• Functional limitation due to OA ≥6 (on a 10 point visual numeric scale), AND
• Patient indicated they may be interested in being referred to a specialist for 
evaluation for potential joint replacement surgery.
Appendix AC. Technical Appendix
Table A1C1
Estimated means, 95% Confidence Intervals (CIs) for WOMAC Total Score from Linear 













6 months 43.1 41.6 −2.5 (−5.9, 0.9) 0.14
12 months 48.1 44.8 −4.4 (−7.5, −1.2) 0.008
Continuous Outcome Code for primary and secondary outcomes
title “Mixed analysis w/ race stratification for WOMACTotal”;
 ods output estimates=estimates_womactotal;
 proc mixed data=analyzeall order=data;
 class physicianid studyid studyper;
 model womactotal=c_racestrata c_mdstrata month6 month12 month6*Randgrp 
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month12*Randgrp/ solution ddfm=kr outPm=OutPred cl;
 random physicianid;
 repeated studyper /subject=studyid type=un rcorr;
 estimate 'common baseline' intercept 1 /cl;
 estimate 'UC 6-month' intercept 1 month6 1 /cl;
 estimate 'TRT 6-month' intercept 1 month6 1 month6*Randgrp 1 /cl;
 estimate 'UC 12-month' intercept 1 month12 1 /cl;
 estimate 'TRT 12-month' intercept 1 month12 1 month12*Randgrp 1 /cl;
 estimate 'UC 12-month-baseline' month12 1 /cl;
 estimate 'TRT 12-month-baseline' month12 1 month12*Randgrp 1 /cl;
 run;
CHAMPS Outcome Code
title “Mixed analysis on change for c&outcome.”;
 proc mixed data=changes order=data plot;
 class physicianid studyid ;
 model cmodexerfrq=modexerfrq c_racestrata c_mdstrata Randgrp/ solution 
ddfm=kr residual cl;
 random physicianid;
 estimate 'UC 12-month' intercept 1 modexerfrq &bmean. /cl;
 estimate 'TRT 12-month' intercept 1 modexerfrq &bmean. Randgrp 1 /cl;
 run;
2. Multiple Imputation Procedure
We conducted a sensitivity analysis using a multiple imputation (MI) approach that included 
additional variables beyond those in our random effects models to strengthen the MAR 
assumption. As a first step, we used t-tests and chi-square tests as appropriate to assess each 
potential variable’s association with missingness at month 12, and any variable with an 
association p-value of 0.25 or less was included in the imputation model along with 
variables included in our primary analysis model (treatment arm and stratification variables). 
Variables assessed included Age, Gender (Male/Female), High School education or less 
(yes/no), Married or living with partner (yes/no), Inadequate income (yes/no), Employed or 
student (yes/no), Disabled (yes/no), Fair or poor health (yes/no), BMI, Self-reported joints 
with OA (Knees only vs. Hips only vs Both Knees and Hips), Duration of symptoms, 
baseline SPPB score, baseline PHQ score, baseline CHAMPS scores, Number of content 
calls completed, MD Gender and MD type. Of these, the following were associated with 
missing status at month 12 and therefore included in the imputation model: Age, Inadequate 
income (yes/no), Disabled (yes/no), baseline PHQ score, and Number of content calls 
completed, The imputation model additionally included randomization arm, stratification 
variables (patient race, and dichotomous variable for percentage of female patients in 
provider panel (≤ 15% vs. > 15%) ), and all collected WOMAC scores at the 3 possible time 
points. Missing WOMAC measurements at any of the 3 time points were imputed using a 
Markov chain Monte Carlo (MCMC) algorithm with 10 imputations. The imputation 
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provided results that were very similar to the main analysis. Models run on the imputed 
datasets estimated WOMAC to be 4.2 point lower (better) in the OA intervention arm than 
Usual Care (95% CI, −7.2, −1.1; p=0.007) at 12 months.
PROC MI Code
/* Main imputation with the covariates that are associated with month 12 
missingness above */
proc mi data = out.allobs out = MIprep
nimpute =10 seed = 43765;
mcmc chain = single
       initial = EM
       niter = 200
       nbiter = 400
       acfplot(wlf) /* or plots=acf */
       timeplot(wlf) /* or plots=trace */
       ;
var randgrp c_racestrata c_mdstrata agecalc disabled phqscore 
contentcalls_imp income womactotal1-womactotal3;
run;













/* Analyze imputated data that was imputed with the additional covariates */
proc mixed data=milong;
 by _imputation_;
 class physicianid studyid studyper;
 model womactotal=c_mdstrata c_racestrata month6 month12 month6*Randgrp 
month12*Randgrp/ solution ddfm=kr outPm=OutPred cl;
 random physicianid;
 repeated studyper /subject=studyid type=un rcorr;
 estimate 'common baseline' intercept 1 /cl;
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 estimate 'UC 6-month' intercept 1 month6 1 /cl;
 estimate 'TRT 6-month' intercept 1 month6 1 month6*Randgrp 1 /cl;
 estimate 'UC 12-month' intercept 1 month12 1 /cl;
 estimate 'TRT 12-month' intercept 1 month12 1 month12*Randgrp 1 /cl;
 estimate 'TRT 12 month - UC 12 month' month12*randgrp 1/cl;
 ods output SolutionF=MIMixedOutcome covB=mixcovBOutcome 
estimates=estOutcome;
 run;
proc sort data=estoutcome; by label _imputation_; run;
title 'Results of 10 imputations, with additional covariates in imputation 
model';





Box plot of WOMAC by Provider, Randomization Arm, and Time Period^
^ Box on box plot indicates the interquartile range, dash is the median, diamond is the mean, 
upper and lower lines extend to the max and min values, respectively.
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* One patient switched from a Usual Care Provider to an Osteoarthritis Intervention 
Provider before being notified of randomization and was analyzed with the Osteoarthritis 
Intervention Group.
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Table 1
Provider and Patient Participant Characteristics at Baseline






Mean Study Patients Per Provider (SD) 10 (2.1) 9.9 (1.7) 10.1 (2.5)
< 15% Females in Patient Panel N (%) 25 (83.3) 13 (86.7) 12 (80.0)
Men N (%) 12 (40.0) 5 (33.3) 7 (46.7)
Provider Type N (%)
 Physician 19 (63.3) 9 (60.0) 10 (66.7)
 Nurse Practitioner 3 (10.0) 0 (0) 3 (20.0)
 Physician Assistant 7 (23.3) 6 (40.0) 1 (6.7)
 Registered Nurse 1 (3.3) 0 (0) 1 (6.7)






Mean age (SD), y 61.1 (9.2) 61.7 (9.0) 60.4 (9.4)
Men N (%) 272 (90.7) 141 (94.6) 131 (86.8)
Non-White Race N (%) 150 (50.0) 75 (50.3) 75 (49.7)
Married or Living with Partner N (%) 199 (66.3) 106 (71.1) 93 (61.6)
High School Education or Less N (%) 81 (27.0) 44 (29.5) 37 (24.5)
Inadequate Income N (%) 103 (34.3) 48 (32.2) 55 (36.4)
Employed or Student N (%)* 127 (42.8) 60 (40.5) 67 (45.0)
Disabled N (%)* 98 (33.0) 53 (35.8) 45 (30.2)
Fair or Poor Health N (%) 115 (38.3) 57 (38.3) 58 (38.4)
Mean Body Mass Index (SD), kg/m2 33.8 (5.8) 33.4 (5.7) 34.3 (6.0)
Joint(s) with OA N (%)
 Knee Only 238 (79.3) 124 (83.2) 114 (75.5)
 Hip Only 32 (10.7) 14 (9.4) 18 (11.9)
 Knee and hip 30 (10.0) 11 (7.4) 19 (12.6)
Mean duration of arthritis symptoms
(SD), y*
14.2 (11.6) 14.6 (12.1) 13.8 (11.1)
Mean WOMAC score (SD)* 48.4 (17.5) 47.8 (17.4) 48.9 (17.6)
Mean SPPB score (SD)* 8.0 (2.6) 8.1(2.5) 8.0 (2.6)
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Mean PHQ-8 Score (SD)* 6.8 (5.4) 6.4 (5.1) 7.2 (5.6)
Median frequency of All Exercise per
week; CHAMPS (IQR)* 14.0 (8.0, 23.0) 14.0 (8.0, 23.5) 14.0 (9.0, 22.0)
Median duration of All Exercise - hours
per week; CHAMPS (IQR)* 10.0 (4.8, 17.3) 10.8 (5.0, 17.9)) 9.8 (4.8, 16.8)
Median frequency of Moderate or
Greater Intensity Exercise per week;
CHAMPS (IQR)* 5.0 (2.0, 10.0) 5.0 (2.0, 10.0) 5.0 (2.0, 9.0)
Median duration of Moderate or
Greater Intensity Exercise - hours per
week; CHAMPS (IQR)* 3.5 (0.5, 8.3) 3.5 (0.5, 9.5) 2.8 (0.5, 7.8)
OA=Osteoarthritis; SD=Standard Deviation; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; SPPB=Short 
Performance Physical Battery; PHQ-8=Patient Health Questionnaire-8; CHAMPS=Community Health Activities Model Program for Seniors; 
IQR=Interquartile Range
*
<= 4 participants missing data for employment, duration of arthritis, WOMAC, PHQ-8; CHAMPS; 16 participants are missing data for the SPPB 
score (11 in OA intervention and 5 in the control group)
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Table 2













Baseline 48.4 n/a n/a
6 months 43.5 41.2 −2.3 (−5.6, 0.9) 0.162
12 months 48.5 44.4 −4.1 (−7.2, −1.1) 0.009
WOMAC Pain Subscale
Baseline 10.2 n/a
6 months 8.7 8.5 −0.2 (−0.9, 0.5) 0.59
12 months 9.9 9.4 −0.5 (−1.2, 0.2) 0.126
WOMAC Function Subscale
Baseline 33.8 n/a n/a
6 months 30.7 28.7 −1.9 (−4.4, 0.6) 0.127
12 months 34.3 31.0 −3.3 (−5.7, −1.0) 0.005
Physical Function (SPPB)
Baseline 8.0 n/a n/a
12 months 7.6 7.8 0.3 (−0.3, 0.9) 0.38
Depressive Symptoms (PHQ-8)
Baseline 6.8 n/a n/a
12 months 6.8 6.2 −0.6 (−1.5, 0.3) 0.160
Change from Baseline in
Weekly Frequency of all
Exercise (CHAMPS)
12 months −0.3 3.0 3.3 (0.8,5.8) 0.009
Change from Baseline in
Duration (Hours per Week) of
All (CHAMPS)
12 months 0.2 3.9 3.6 (1.3,5.9) 0.003
Change from Baseline on
Weekly Frequency of Moderate
or Greater Intensity Exercise
(CHAMPS)
12 months −1.1 0.5 1.6 (0.1,3.1) 0.042
Change from Baseline in
Duration (Hours per Week) in
Moderate or Greater Intensity
Exercise (CHAMPS)
12 months −0.5 1.2 1.6 (0.3,2.9) 0.017
Body Mass Index
Baseline 33.8 n/a n/a
12 months 33.6 33.5 −0.1 (−0.5, 0.2) 0.47
OA=Osteoarthritis; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index; SPPB=Short Performance Physical Battery; 
PHQ-8=Patient Health Questionnaire-8; CHAMPS=Community Health Activities Model Program for Seniors
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&
Linear Mixed Model Results; ^37 participants (21 OA Intervention, 16 Usual Care) and 27 participants (15 OA Intervention; 12 Usual Care) have 
no follow-up data for 6 and 12 months, respectively; additional missing across all time points due to scoring algorithms, refusal to participate, ≤ 6 
participants missing WOMAC scores (1 baseline; 2 OA Intervention, 1 Usual Care 6 months; 1 OA Intervention, 1 Usual Care 12 months); 55 
missing SPPB score (16 baseline;, 21 OA Intervention, 18 Usual Care 12 months); 19 missing PHQ scores (4 baseline, 5 OA Intervention, 10 Usual 
Care 5, 12 months); 11 missing frequency and duration of exercise (1 baseline, 4 OA Intervention, 6 Usual Care 12months); 4 missing measured 
BMI (3 OA Intervention, 1 Usual Care)
*
Difference of estimated treatments may not match estimated difference in means exactly due to rounding
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Table 3






















Physical Therapy† 10 (6.7) 2 (20.0) 18 (11.9) 1 (5.6)
    Knee OA 1 (10.0) 0 (0.0)
    Hip OA 1 (10.0) 1 (5.6)
Knee Brace 17 (11.4) 3 (17.6) 29 (19.2) 5 (17.2)
MOVE! Program 5 (3.4) 2 (40.0) 30 (19.9) 8 (26.7)
Orthopedic Visit† 9 (6.0) 6 (66.7) 8 (5.3) 4 (50.0)
    Knee OA 5 (55.6) 3 (37.5)
    Hip OA 1 (11.1) 1 (12.5)
Joint Injection 16 (10.7) 7 (4.7) 14 (9.3) 8 (5.3)
OA=Osteoarthritis; PA=Physical Activity
^
Missing data: Treatment receipt: Topicals −16 Usual Care, 16 OA Intervention; Pain Medication – 12 Usual Care, 15 OA Intervention,
*
For physical therapy, knee braces, MOVE! and orthopedic visits, proportions are calculated using participants with referrals (during the study 
period) as the denominator. For joint injections (which can be done by a primary care provider without a specialty consult), proportions are 
calculated using all participants in the study arm as the denominator.
†
Referrals for physical therapy and orthopedic visits did not differentiate between hip and knee OA
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Table 4



















Physical Therapy† 74 (49.0) 15 (20.3) 1 (6.7)
    Knee OA 0 (0.0)
    Hip OA 1 (6.7)
Knee Brace 62 (41.1) 22 (35.5) 2 (9.1)
MOVE! Program ‡ 131 (86.8) 30 (22.9) 8 (26.7)
  Weight and PA 110 (72.9) 25 (22.7) 7 (28.0)
  Weight Only 14 (9.3) 2 (14.3) 0 (0.0)
  PA only 7 (4.6) 3 (42.9) 1 (33.3)
Orthopedic Visit† 18 (11.9) 2 (11.1) 0 (0.0)
    Knee OA 0 (0.0)
    Hip OA 0 (0.0)
Joint Injection 33 (21.9) N/A 9(27.3)
Topical NSAID or




125 (82.8) N/A 46 (36.8)
OA=Osteoarthritis; PA=Physical Activity; PCP = Primary Care Provider; NSAID=Nonsteroidal Anti-inflammatory Drug
^
Missing data: Treatment recommendations, 8 participants unable to issue reccomendations; Treatment receipt: Topicals −16 Usual Care, 16 OA 
Intervention; Pain Medication – 12 Usual Care, 15 OA Intervention,
**
Proportion is based on participants with recommendation as the denominator
***
For physical therapy, knee braces, MOVE! and orthopedic visits, proportions are calculated using participants with participants that received 
treatment recommendations and referrals (during the study period) as the denominator. For joint injections (which can be done by a primary care 
provider without a specialty consult), topical,pain medication variables, proportions are calculated using participants that received treatment 
recommendations as the denominator.
†
Treatment recommendations and referrals for physical therapy and orthopedic visits did not differentiate between hip and knee OA;
‡
Participants could receive MOVE! recommendations for physical activity, weight management or both. These recommendations are listed 
separately, but provider referrals and MOVE! visits did not differentiate.
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